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Abstract (170/170) 
Alzheimer’s disease (AD) patients display hippocampal atrophy, memory impairment, and 
cognitive decline. New neurons are generated throughout adulthood in two regions of the brain 
implicated in AD, the dentate gyrus of the hippocampus and the sub-ventricular zone of the 
olfactory bulb. Disruption of this process contributes to neurodegenerative diseases including 
AD and many of the molecular players in AD are also modulators of adult neurogenesis. 
However, the genetic mechanisms underlying adult neurogenesis in AD have been under-
explored. To address this gap, we performed a gene-based association analysis in cognitively 
normal and impaired participants using neurogenesis pathway-related candidate genes curated 
from existing databases, literature mining, and large-scale genome-wide association study 
findings. A gene-based association analysis identified ADORA2A as significantly associated 
with hippocampal volume and the association between rs9608282 within ADORA2A and 
hippocampal volume was replicated in the meta-analysis after multiple comparison adjustments 
(p=7.88x10-6). The minor allele of rs9608282 in ADORA2A is associated with larger 
hippocampal volumes and better memory. 
1. Introduction 
Adult neurogenesis occurs throughout life in specific regions of the brain in humans. In rodents, 
neural stem cells differentiate to new neurons in several regions of the brain, but studies show 
that adult neurogenesis is limited to the dentate gyrus (DG) of the hippocampus and the sub-
ventricular zone of the olfactory bulb in humans (Eriksson, Perfilieva et al. 1998, Spalding, 
Bergmann et al. 2013, Bond, Ming et al. 2015). The hippocampus is the most important region 
of the brain for new learning and episodic/spatial memory. The new neurons generated during 
adult neurogenesis are incorporated into hippocampal network circuitry during construction and 
maintenance of neural circuits and contribute to learning and memory (Aimone, Li et al. 2014, 
Winner and Winkler 2015). The progenitor cells in DG divide periodically, and DG experiences 
stability in neurogenesis throughout life (Scharfman and Bernstein 2015, Horgusluoglu, 
Nudelman et al. 2016). In rodents, neural stem cells (NSCs) in the DG make approximately 
8,000 to 10,000 new neurons per day. However, the proportion of hippocampal neurogenesis 
decline in human is smaller than mice with aging (Amrein, Isler et al. 2011, Spalding, Bergmann 
et al. 2013). In 1998, the presence of adult-born neurons in the dentate gyrus of the human 
hippocampus had been identified by using cancer patients who had received the labelled 5-
bromo-2'-deoxyuridine (BrdU) in hippocampal neurons (Eriksson, Perfilieva et al. 1998). In 
adults, the annual turnover of stem cells into neurons is 1.75% with a modest decline during 
aging (Spalding, Bergmann et al. 2013). By contrast, the estimated annualized hippocampal 
atrophy rate is 1.41% per year for cognitively normal older people and 4.66% for patients with 
AD pathology (Barnes, Bartlett et al. 2009). Disruption of adult neurogenesis process has been 
postulated to contribute to neurodegenerative diseases including AD. Alterations in hippocampal 
neurogenesis in AD could either provide protection by proliferation of neural progenitor cells or 
cause accelerated neural degeneration due to impairment of neuronal networks and synaptic 
plasticity. Several studies in mice have combined structural MRI and histological approaches to 
investigate newborn neurons and neural stem/progenitor cells in neurogenesis-related brain 
regions and found that neurogenesis was associated with increased gray matter volume 
(Biedermann, Fuss et al. 2016). The relationship between hippocampal volume and adult 
neurogenesis in the human brain has not been studied yet. 
Many molecular mechanisms and pathways play a role in the hippocampal neurogenesis 
process , including the proliferation of neural progenitor cells, the differentiation, migration, and 
maturation of adult neurons (Urban and Guillemot 2014, Horgusluoglu, Nudelman et al. 2016). 
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Known modulators of adult neurogenesis include signaling transduction, vascular and immune 
systems, metabolic factors, and epigenetic regulation (Urban and Guillemot 2014, Borsini, 
Zunszain et al. 2015, Horgusluoglu, Nudelman et al. 2016). In particular, multiple factors such 
as neurotrophic factors, transcription factors, and cell cycle regulators control NSC proliferation, 
maintenance in neurogenic niche, and differentiation into mature neurons; these factors play 
role in networks of signaling molecules that influence each other during construction of neural 
circuits, and contribute to learning and memory (Fig. 1).  
Disruption of the neurogenesis process has been postulated to contribute to neurodegenerative 
diseases including AD (Marlatt and Lucassen 2010). However, the mechanisms by which AD 
pathology affects neurogenesis are not completely understood. Alterations in the early stages of 
AD, such as amyloid-β deposition and inflammation, may impair the maturation of newborn 
neurons and inhibit hippocampal neurogenesis (Mu and Gage 2011). Genetic changes in 
neurogenesis-related pathways and genes may also play important roles in the alteration of 
NSCs maturation into newborn neurons (Horgusluoglu, Nudelman et al. 2016). Pathway- or 
gene-based association analysis has been used to study a number of complex 
neurodegenerative diseases, including AD, using a wide variety of phenotypes, including 
cerebrospinal fluid Aβ1-42 peptide level (Han, Schellenberg et al. 2010, Kim, Swaminathan et 
al. 2011), cerebral amyloid deposition (Swaminathan, Shen et al. 2012), brain glutamate levels 
(Baranzini, Srinivasan et al. 2010), and episodic memory (Ramanan, Kim et al. 2012). However, 
no study to date has evaluated the association between candidate neurogenesis-related genes 
and hippocampal volume. Thus, the goal of the present study was to perform a gene-based 
association analysis of neurogenesis pathway-related candidate genes in cognitively normal 
and impaired participants from ADNI cohort. Identification of genes that play a role in both 
hippocampal neurogenesis and AD may hold great promise for better understanding the role of 
neurogenesis in AD, as well as to aid in discovery of novel therapeutic targets for AD. 
We used well-characterized participants from extensively studied cohort Alzheimer’s Diasease 
Neuroimaging Initiatives (ADNI), which uniquely have GWAS data sets on the same participants 
as well as multi-modal structural and functional neuroimaging (MRI, PET) data. A quantitative 
phenotype approach to genetic association studies provides the advantage of increased power 
sizes to detect significant genetic effects as compared to a traditional case-control design. We 
used hippocampal volume as a quantitative phenotype measured by MRI imaging, metabolic 
activity and amyloidosis in the hippocampus measured by PET imaging, and composite memory 
scores as quantitative traits to investigate that adult hippocampal neurogenesis-related genes 
and pathways are significantly associated with AD-related endophenotypes.  
 
Highlights: 
• Candidate pathways and genes which play a role in neurogenesis in the adult 
brain are manually-curated. 
• ADORA2A is significantly associated with hippocampal volume 
• A SNP (rs9608282) upstream of ADORA2A is associated with larger 
hippocampal volume and better memory performance. 
• rs9608282 may have a protective effect on brain structure and function in 
neurogenesis-related brain regions. 
• There is a significant interaction effect of NMDA-receptor antagonist use and the 
ADORA2A rs9608282-T on memory performance. 
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2. Materials and Methods 
2.1. Participants 
We used the participants of the Alzheimer's Disease Neuroimaging Initiative Phase 1 (ADNI-1) 
and its subsequent extensions (ADNI-GO/2) for this study. ADNI was launched in 2004 by the 
National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, the 
Food and Drug Administration (FDA), private pharmaceutical companies, and nonprofit 
organizations as a public-private partnership. The aim of ADNI has been to identify whether 
serial MRI, positron emission tomography (PET), sensitive and specific other markers, and 
clinical and neuropsychological assessments could be combined to measure the progression of 
mild cognitive impairment (MCI) and early AD. Participants aged 55-90 in ADNI cohort include 
approximately 400 cognitively normal older individuals (CN), 100 individuals with significant 
memory concerns (SMC), 800 individuals diagnosed with MCI, and 300 individuals diagnosed 
with AD. Clinical and neuroimaging procedures and the other information about the ADNI cohort 
can be found at http://www.adni-info.org/.  
After the initial analysis, a meta-analysis was conducted with ADNI (Nho, Corneveaux et al. 
2013, Weiner, Veitch et al. 2013) and two independent datasets, including the AddNeuroMed 
study (N=218; 66 CN, 77 MCI, 76 AD) (Lovestone, Francis et al. 2009, Nho, Corneveaux et al. 
2013), and the Indiana Memory and Aging Study (IMAS) study (N=59; 29 CN, 24 MCI, 6 AD) 
(Nho, Corneveaux et al. 2013). 
Written informed consent was obtained from each participant and all protocols were approved 
by each participating study and site’s Institutional Review Board. 
 
2.1.1. Subject selection 
Only non-Hispanic Caucasian participants were selected for this analysis by genetic clustering 
with CEU (Utah residents with Northern and Western European ancestry from the CEPH 
collection) and TSI (Tuscans in Italy) populations using HapMap 3 genotype data and 
multidimensional scaling (MDS) analysis after performing standard quality control (QC) 
procedures for genetic markers and participants (Ramanan, Risacher et al. 2014). Overall, 
1,563 non-Hispanic Caucasian participants were included, as their genome-wide association 
study (GWAS) data passed the above population stratification and all other standard QC 
procedures (Kim, Swaminathan et al. 2011). Demographic information is shown in Table 1 for 
these participants.   
 
2.2. Identification of candidate genes 
Candidate genes which control the turnover process of neural stem cells/precursors to new 
functional neurons during adult neurogenesis were manually curated using a pathway-based 
systems biology approach (Fig. 1). Genes from known modulators of adult neurogenesis include 
those involved in signaling transduction, vascular and immune system function, metabolic 
factors, and epigenetic regulation (Nho, Corneveaux et al. 2013, Funa and Sasahara 2014, 
Urban and Guillemot 2014, Yao and Jin 2014, Borsini, Zunszain et al. 2015). Pathway-based 
approaches were used to manually curate these hippocampal neurogenesis-related genes 
through a review of existing databases and literature mining, resulting in a final gene list (Fig. 2). 
Specifically, we identified hippocampal neurogenesis-related genes using four publicly available 
databases (GoGene, Qiagen RT2 Profiler PCR Arrays, Gene Ontology (GO) with Gene Set 
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Enrichment Analysis (GSEA), and Mammalian Adult Neurogenesis Gene Ontology (MANGO)) 
and literature mining.  
GoGene contains high-quality manual annotation with high-throughput text mining from 
literature using ontology terms. This database includes associations between genes and gene-
related terms for ten model organisms extracted from more than 18,000,000 PubMed entries 
that cover process, function, location of genes and their relationship with diseases and 
compounds (http://gopubmed.org/gogene) (Plake, Royer et al. 2009). We performed a search 
for GoGene term “adult neurogenesis” to identify neurogenesis-related genes.  
Qiagen RT2 Profiler PCR Arrays are the one of the most reliable tools to analyze the expression 
of genes related to specific pathways. The human Neurogenesis RT² Profiler™ PCR Array 
contains 84 genes, manually curated using literature mining, which are highly related to the 
process of neurogenesis, such as neural stem/progenitor cells proliferation, differentiation, 
migration, and maturation into newborn neurons (www.qiagen.com). Growth factors, 
inflammatory cytokines, cell adhesion molecules, and cell signaling genes involved in the 
neurogenesis process were also represented in this profiling array. We included all genes from 
this Neurogenesis array in our gene list.  
DAVID (the Database for Annotation, Visualization, and Integrated Discovery) is a publicly 
available functional tool which includes annotations from Gene Ontology (GO). Gene Set 
Enrichment Analysis (GSEA) pathway annotations were downloaded from Molecular Signatures 
Database version 5.0 (http://software.broadinstitute.org/gsea/msigdb). This annotation data 
comprised a collection of GO. A GO annotation contains a GO term associated with a specific 
reference which expresses the target or analysis associated with a specific gene product. Each 
GO term belongs to molecular function (Naveh, Shahar et al.), cellular component (CC), or 
biological process (BP). “Neurogenesis” was used as the GO term in this analysis to identify 
neurogenesis related gene sets from the GSEA database.  
We also used MANGO, which consists of 259 genes designed and curated by Overall et al. 
(Overall, Paszkowski-Rogacz et al. 2012). In MANGO, all genes are classified by their positive, 
negative, or neutral effect on hippocampal neurogenesis and thusly annotated. We used 
recently updated MANGO version 3.1 to annotate genes.  
We identified 510 genes from GoGene, 84 genes from Neurogenesis RT² Profiler™ PCR Array, 
259 genes from MANGO database, and 93 genes from GSEA/Molecular Signatures Database. 
We combined all genes related to neurogenesis from the four databases (N=748). Then, each 
gene related to hippocampal neurogenesis was annotated from relevant literature. Initial 
Pubmed search using the keywords “adult hippocampal neurogenesis” for papers published 
until 9/2016 included 2,717 articles. We used Pubmed to identify if all 748 genes are related to 
hippocampal neurogenesis from 2,717 articles.  After literature mining, among 748 genes, only 
401 genes were related to adult hippocampal neurogenesis.  
Finally, since a key goal was to identify candidate genes playing a role in both adult 
hippocampal neurogenesis and AD pathology, we focused on hippocampal neurogenesis-
related genes which are also implicated in AD. For this purpose, we identified AD-associated 
susceptibility genes using the AlzGene database (http://www.alzgene.org/), which provides a 
comprehensive meta-analysis of genes previously identified in various AD association studies, 
and large-scale AD GWAS results (N=680) (Lambert, Ibrahim-Verbaas et al. 2013). The 
AlzGene database consists of a comprehensive, unbiased, publicly available catalog of all 
genetic association studies in the field of AD, which was identified from published papers by 
pubMed search using keywords “alzheimer* AND (genet* OR associat*)”. The gene list in 
AlzGene represents a summary of promising AD candidate genes. We then compared this gene 
list to the 401 genes previously identified as involved in adult hippocampal neurogenesis to filter 
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the lists to 81 common genes related to both hippocampal neurogenesis and AD. These 81 
genes were used in the association analysis. 
2.3. Endophenotypes  
Pre-processed baseline 1.5T and 3T MRI scans from 1,563 participants were downloaded from 
ADNI public website (http://adni.loni.usc.edu). FreeSurfer version 5.1 was used to extract total 
hippocampal and hippocampal subfield volumes, as well as total intracranial volume (ICV) 
(Dale, Fischl et al. 1999, Fischl, Sereno et al. 1999, Risacher, Kim et al. 2013, Risacher, Kim et 
al. 2015). Total hippocampal volume, as well as selected adult neurogenesis-related subfield 
volumes (CA1, CA23, CA4, and DG) (N=1,563), were used as endophenotypes for the 
association analysis. In addition, we used a composite score of episodic memory (N=1,563)  
(Crane, Carle et al. 2012) and CSF total tau levels (N=1,112) as endophenotypes to further 
characterize neurodegeneration (Shaw, Vanderstichele et al. 2009, Shaw, Vanderstichele et al. 
2011).  
 
2.4. Genotyping and Quality Control 
ADNI samples were genotyped using Human 610-Quad, HumanOmni Express, and 
HumanOmni 2.5M BeadChips. Sample and SNP quality control procedures of GWAS data such 
as SNP call rate < 95%, Hardy-Weinberg equilibrium test p < 1 × 10−6, and frequency filtering 
(MAF ≥ 5%) were performed (Purcell, Neale et al. 2007, Saykin, Shen et al. 2010, Hohman, 
Koran et al. 2014, Ramanan, Risacher et al. 2014). Imputation of un-genotyped SNPs was 
performed using MaCH (Markov Chain Haplotyping) software based on the 1000 Genomes 
Project as a reference panel (Howie, Fuchsberger et al. 2012).  
 
2.5. Association Analysis and Meta-Analysis 
SNPs from the 81 candidate genes were located in untranslated regions (Laussu, Khuong et al. 
2014), 3′ UTR, 5′ UTR, coding regions, intronic regions, and regulatory regions (±20 kb of 
upstream and downstream regions).  A gene-based association analysis of hippocampal 
neurogenesis pathway-related candidate genes was performed in an additive genetic model 
using a set-based test in Plink v1.07 (http://pngu.mgh.harvard.edu/~purcell/plink/) (Purcell, 
Neale et al. 2007). After frequency and genotyping pruning, 18407 SNPs remained from 81 
genes. (Purcell, Neale et al. 2007). After frequency and genotyping pruning, 18407 SNPs 
remained from 81 genes. A mean test statistic for each SNP within a gene was computed to 
determine other SNPs in linkage disequilibrium (LD; i.e., r2>0.5). A quantitative trait analysis 
(QT) was then performed with each SNP. For each gene (set), the top independent SNPs (i.e., 
not in LD; maximum of 5) were selected if their p-values were less than 0.05 in the QT analysis. 
The SNP with the smallest p-value was selected first; subsequent independent SNPs were 
selected in order of decreasing statistical significance. From these subsets of SNPs, the statistic 
for each set was calculated as the mean of these single SNP statistics. The analysis was 
performed to estimate the additive effect of the selected SNP minor allele on the phenotypic 
mean (Purcell, Neale et al. 2007, Swaminathan, Shen et al. 2012). Covariates included gender, 
age, years of education, ICV, MRI field strength (1.5T vs 3T) and diagnosis status. An empirical 
p-value (20,000 permutations) was reported for each gene. In the discovery sample (ADNI-
1/GO/2), a conservative significance threshold (p < 0.00061) was used based on Bonferroni 
correction for 81 genes. We subsequently performed a meta-analysis for genes and SNPs 
associated with hippocampal volume using data from the ADNI-1/GO/2, AddNeuroMed, and 
IMAS cohorts. The gene-based meta-analysis was performed using the weighted z statistic test 
(Stouffer’s weighted z statistic) as implemented in R, with weight accounting for the sample size 
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of each cohort. For SNP-based meta-analysis, METAL was used with a fixed-effect inverse 
variance model (Willer, Li et al. 2010). For meta-analysis, effect sizes were provided by 
standardized β coefficients from linear regression. 
We also evaluated the effect of the minor allele rs9608282-T on hippocampal volume and 
composite memory score after the participants, which included only those diagnosed with MCI 
or AD, were classified as either a Memantine user (NMDA (+)) or a Memantine non-user (NMDA 
(-)) using two-way analysis of covariance (ANCOVA) for continuous variables and a chi-square 
for categorical variables implemented in SPSS 23.0. In addition, two-way analysis of covariance 
(ANCOVA) was used to examine the effect of the minor allele (rs9608282-T) on hippocampal 
volume in both amyloid-negative and amyloid-positive participants (classified as positive or 
negative by either baseline [18F]Florbetapir PET scans and/or CSF Aβ1-42 level). 
 
3. Results 
 
3.1. Gene-based and SNP-based analysis of mean volumes of hippocampus 
and hippocampal sub-regions 
The manual gene/pathway curation for hippocampal neurogenesis yielded 18407 SNPs in 81 
genes (Fig. 2). In the discovery sample, the gene-based association analysis showed that 
APOE and ADORA2A were significantly associated with hippocampal volume after Bonferroni 
correction (p-value=5x10-5; Table 2).  
One SNP (rs9608282) upstream of ADORA2A was most significantly associated with total 
hippocampal volume and sum of the hippocampal sub-region volumes (p = 1.14x10-5 and 
2.5x10-4, respectively; Table 3). Specifically, participants with no copies of the minor allele 
(N=1,317; GG genotype) had a smaller mean hippocampal volume compared to participants 
with one copy of the minor allele (N=236; TG genotype) or participants with two copies of the 
minor allele (N=10; TT genotype).  
For replication of our major significant SNP finding, we analyzed independent samples from the 
ADNI, AddNeuroMed IMAS cohorts. SNP-based meta-analysis of ADORA2A in three 
independent cohorts (ADNI1/GO/2, AddNeuroMed, and IMAS) identified that rs9608282-T in 
ADORA2A are significantly associated with hippocampal volume (p = 0.000043, N=1,840, Table 
4; p = 7.88x10-6, N= 1,840, Table 5, respectively). In ADNI1/GO/2, AddNeuroMed cohorts 
except IMAS, rs9608282-T exhibited a positive direction of effect on hippocampal volume. 
Following the SNP-based association analysis, we performed a post-hoc analysis to measure 
the interaction effect of APOE and the ADORA2A SNP on hippocampal volume. There was no 
evidence of epistasis, modeled as interaction between APOE ε4 status and the minor allele of 
rs9608282 (p = 0.54). However, ADORA2A rs9608282-T and APOE ε4 exhibited independent 
but opposite effects on hippocampal volume (Fig. 3A, 3B), with a comparable effect sizes 
between the APOE ε4 allele and the presence of at least one copy of the minor allele at 
rs9608282. Participants carrying at least one copy of the minor allele of the ADORA2A SNP 
have larger hippocampal volumes than those without the minor allele, even in participants with 
APOE ε4 (p=0.001; Fig. 3C). The positive effect of the ADORA2A rs9608282-T allele on 
hippocampal volume was seen in both amyloid-negative and amyloid-positive participants 
(classified as positive or negative by either baseline [18F]Florbetapir PET scans and/or CSF 
Aβ1-42 level). Specifically, rs9608282-T was significantly associated with larger hippocampal 
volumes in Aβ negative (p-value = 0.027) and Aβ positive participants (p-value = 0.015, Fig. 4). 
In addition, the association of the rs9608282-T allele with hippocampal volume and 
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neurogenesis-related to sub-regions independent of diagnosis suggests that this effect might be 
a global phenomenon.  
Since previous studies have suggested that ADORA2A plays an important role controlling 
NMDA-dependent synaptic toxicity and memory impairment (Tebano, Martire et al. 2005, Yee, 
Singer et al. 2007, Sarantis, Tsiamaki et al. 2015), we examined the interaction of taking 
Memantine, a NMDA-receptor antagonist, and ADORA2A rs9608282 on hippocampal volume 
and memory performance. Participants diagnosed with MCI or AD were classified as either a 
Memantine user (NMDA+) or a Memantine non-user (NMDA-). We found that NMDA- 
participants carrying at least one copy of the minor allele (T) of the ADORA2A rs9608282 had a 
larger mean hippocampal volume (p<0.001; Fig. 5A). There was a significant interaction effect 
of NMDA-receptor antagonist use and ADORA2A rs9608282 on memory performance (p = 
0.009). NMDA+ participants carrying two copies of the major allele (G) of the ADORA2A 
rs9608282 had better memory performance (Fig. 5B).  
 
3.2. Association of rs9608282 with episodic memory and CSF level of total tau 
Given the association of ADORA2A rs9608282-T with larger hippocampal volume, we 
hypothesized that ADORA2A would also associated with episodic memory scores as they are 
highly related to hippocampal structure. As might be hypothesized, rs9608282-T was 
significantly associated with a better composite memory score (β=0.065; p=0.015) after 
controlling for age, gender, and years of education (Fig. 6). 
A previous study suggested that hyperphosphorylated tau decreases adult neurogenesis in 
mouse model (Komuro, Xu et al. 2015). Therefore, we also assessed the effect of the 
rs9608282-T minor allele on CSF total tau level. As we hypothesized, rs9608282-T carriers 
showed decreased CSF total tau levels relative to non-carriers (β=-0.061; p=0.039), after 
controlling for age and gender (Fig. 7). However, there is no correlations of rs9608282 with CSF 
Aβ and phospho-tau levels. 
Finally, we used gene expression data from the Allen Human Brain Atlas to evaluate if 
ADORA2A was expressed in neurogenesis-related regions in normal brains. ADORA2A was in 
fact highly expressed across the major adult neurogenesis related regions of the brain (Fig. 8) 
and was especially highly expressed in CA1 and CA2.  
 
4. Discussion 
We used well-characterized participants from the Alzheimer’s Disease Neuroimaging Initiatives 
(ADNI), an extensively studied cohort that includes cognitively normal older individuals (CN), as 
well as participants with significant memory concerns (SMC), amnestic mild cognitive 
impairment (MCI), and Alzheimer’s Disease (AD). Using targeted neurogenesis pathway-based 
gene analysis, we discovered a significant association of ADORA2A rs9608282-T with larger 
mean hippocampal volumes and volumes of neurogenesis-related hippocampal sub-regions, 
better episodic memory performance, and reduced CSF total tau. These findings suggested a 
protective effect of this SNP on brain structure and function in neurogenesis-related brain 
regions.  
ADORA2A (Adenosine Receptor Subtype A2a) is a G-protein-coupled adenosine receptor that 
is involved with controlling synaptic plasticity in glutamatergic synapses (Cunha, Ferre et al. 
2008, Krugel 2015). Previous work had indicated a physical and functional interaction of 
ADORA2A with dopamine D2 receptors (Chen, Moratalla et al. 2001). However, A1R–A2AR 
heteromer controls the affinity of agonist binding to A2a receptors in the striatum and localizes 
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in glutamatergic nerve terminals to control glutamate release (Ciruela, Casado et al. 2006). In 
addition to its abundance in the striatum, ADORA2A also plays an important role in 
hippocampus, particularly in neurogenesis in the CA3 region. A previous study demonstrated 
that inhibition of the A2a receptor induced synaptic damage in rat hippocampal nerve terminals 
(Cunha, Canas et al. 2006).  
A reduction of A2a receptors in mice with traumatic brain injury has also been shown to 
decrease cognitive impairment (Ning, Yang et al. 2013). In fact, the adenosine 2a receptor 
localizes in microglial cells and may be a regulation of microglial function in response to brain 
damage (Cunha, Ferre et al. 2008). Since neuroinflammatory blockade is thought to enhance 
neural stem/progenitor cells activity and promote adult neurogenesis, A2a receptor-mediated 
control of neuroinflammation might be a vital mechanism in neurodegenerative diseases (Monje, 
Toda et al. 2003). Inhibition of the A2a receptor also prevents early Aβ-induced synaptotoxicity 
and memory dysfunction through a p38 MAPK-dependent pathway (Canas, Porciuncula et al. 
2009), potentially suggesting additional roles for this receptor in AD. In fact, ADORA2A 
blockade prevented memory decline secondary to amyloid-beta accumulation, which is a major 
pathological hallmark in AD (Cunha, Canas et al. 2008). Another important role of ADORA2A is 
to modulate brain-derived neurotrophic factor (BDNF). Administration of an ADORA2A 
antagonist inhibits the actions of BDNF on GABA and glutamate release from the hippocampal 
nerve terminals (Vaz, Lerias et al. 2015).  In addition, the A2a receptor is involved with control of 
N-methyl-D-aspartate (NMDA) receptor function by co-localizing with metabotropic glutamate 5 
receptors (Glu5R) in hippocampal synapses (Tebano, Martire et al. 2005). The synaptic 
localization of A2a receptors plays a key role controlling NMDA-dependent synaptic 
transmission in the hippocampus (Rebola, Sachidhanandam et al. 2007). In fact, glutamate 
release is dependent on the activation of adenosine A2AR by endogenous adenosine (Canas, 
Porciuncula et al. 2009, Vaz, Lerias et al. 2015). Previous studies showed the relationship 
between NMDA receptor and Adenosine Receptor Subtype A2a, which supports our finding of a 
significant interaction effect of NMDA-receptor antagonist use and the ADORA2A rs9608282-T 
on memory performance. 
rs9608282 is located upstream of ADORA2A (UCSC Genome Browser (GRCh37/hg19)) and is 
characterized by occurring during read-through transcription of two neighbor genes, SPECC1L 
(sperm antigen with calponin homology and coiled-coil domains 1-like) and ADORA2A 
(adenosine A2a receptor) on chromosome 22. This read-through transcription is a candidate for 
nonsense-mediated mRNA decay (NMD), which leads to no protein production. The inhibition of 
ADORA2A has been shown to enhance spatial memory and hippocampal plasticity through 
adult neurogenesis (Laurent, Burnouf et al. 2016). In the present study, rs9608282-T was 
associated with better memory and a larger hippocampal volume, suggesting that this variation 
may inhibit protein production of ADORA2A. Animal models or cell culture studies are needed to 
more completely characterize the function of this variation on brain structure and adult 
neurogenesis. 
Based on gene expression data from postmortem human brains, the A2A receptor is highly 
expressed in neurogenesis-related regions (CA1, CA2, CA3 and dentate gyrus) of the 
hippocampus in the adult human brain. Since the dentate gyrus and CA3 regions are important 
for memory formation and pattern separation processes, as well as for learning new information, 
we believe the observed effect of the rs9608282-T variation may be protective for memory 
performance by altering neurogenesis in these regions. In addition, the association of the 
rs9608282-T allele with hippocampal volume and neurogenesis-related sub-regions 
independent of diagnosis suggests that this effect might be a global rather than AD-specific 
phenomenon. Consistent with protective effect of this variant, decreased CSF total-tau protein 
levels were also observed in participants with at least one minor allele (T) of rs9608282. 
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Interestingly, ADORA2A rs9608282-T and APOE ε4 exhibit an independent but opposite effect 
on hippocampal volume. In sum, we observed a significant protective effect of a variant 
(rs9608282) in the neurogenesis-related ADORA2A gene on brain structure and function, 
including increased hippocampal volume, better memory performance, and reduced CSF tau. 
This finding suggests that the adenosine A2a receptor warrants further investigation as a 
potential target for future therapeutics to treat neurodegenerative disease and cognitive decline. 
The eQTL analysis using the BRAINEAC brain tissue microarray-based gene expression 
database (http://www.braineac.org/) revealed that rs9608282 in ADORA2A is marginally 
associated with ADORA2A gene expression levels in the hippocampus (p-value = 0.172). 
Individuals carrying minor allele rs9608282-T have decreased expression levels in the 
hippocampus, showing a potential protective effect consistent with our SNP-based association 
results with hippocampal volume and memory. Increased ADORA2A levels lead to synaptic 
toxicity and memory impairment (Tebano, Martire et al. 2005, Yee, Singer et al. 2007, Sarantis, 
Tsiamaki et al. 2015). 
The limitation of the present report is that even though we used three independent publicly 
available databases to identify a curated gene list related to adult neurogenesis, it is possible 
that we may have missed other neurogenesis related genes not represented in these 
databases. The other limitation is that even though a few studies combined MRI-based 
hippocampal volume with immunochemistry to reveal that there is a significant hippocampal 
atrophy and the reduction of hippocampal neurogenesis in animal models, it is still not clear if 
hippocampal atrophy is related to adult neurogenesis in humans due to lack of data sources. 
Another limitation for this study is the lack of replication in the gene-based analysis. In the 
AddNeuroMed and IMAS, ADORA2A did not show a significant association with hippocampal 
volume but showed a trend. After combining three independent cohorts, the meta-analysis result 
was significant due to the increased detection power. In addition, future studies are needed to 
identify functional evidence to validate this SNP in ADORA2A. However, the present findings 
support that the ADORA2A gene plays a role in adult neurogenesis. AD is associated with 
hippocampal volume loss the observed effects indicates the potential importance of further 
investigation of this gene in independent cohorts. 
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Table 1. Demographic and clinical characteristics of ADNI participants at the time of MRI scan 
 CN SMC EMCI LMCI AD 
N 367 94 280 512 310 
Age 74.59 (5.57) 71.77 (5.65) 71.14 (7.26) 73.52 (7.65) 74.65 (7.79) 
Gender 
(M/F) 192/175 38/56 158/122 318/194 176/134 
Education 16.32 (2.68) 16.81 (2.57) 16.08 (2.67) 15.97 (2.91) 15.23 (2.97) 
APOE 
(ε4−/ε4+) 267/99 62/32 160/119 232/280 104/206 
 
Table 2. 81 genes of gene-based association results in the discovery sample for hippocampal 
volume using common variants (MAF ≥ 0.05) where empirical p-values were calculated using 
20,000 permutations in PLINK 
 
 
 
Gene Number 
of SNPs 
in gene 
Number of 
significant 
SNPs 
(p<0.05, 
r2<0.5) 
Empirical 
gene-based 
p-value 
List of significant SNP 
ADORA2A 55 1 5X10-5 rs9608282 
APOE 85 5 5X10-5 rs429358|rs7259620|rs34095326| 
rs4803770|rs157580 
TLR4 58 2 0.01499 rs11789302|rs10759930 
BCHE 201 4 0.02797 rs2686409|rs1355538|rs12107166| 
rs6807910 
CXCL10 42 1 0.04795 rs4256246 
S100B 220 1 0.05994 rs118078026 
CXCL12 306 4 0.06194 rs11238990|rs11238991|rs1144472| 
rs17659345 
TET1 387 3 0.06593 rs113716271|rs12776586|rs12221107 
BCL2 368 5 0.07493 rs9957149|rs28564323|rs7236090| 
rs6567334|rs11872403 
PTGS2 52 2 0.08492 rs7547677|rs2206593 
ACHE 51 2 0.08791 rs13245899|rs73714210 
SORL1 233 2 0.09091 rs9665907|rs643010 
SLC6A4 63 1 0.09191 rs16965628 
GRIN2B 1054 5 0.0999 rs34870448|rs11612709|rs12582848| 
rs11611667|rs2300256 
NGFR 86 5 0.0999 rs584589|rs11466150|rs2072444| 
rs535717|rs2537710 
MEF2C 232 1 0.1019 rs1065861 
CXCL1 39 1 0.1039 rs2968710 
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NR3C1 238 5 0.1209 rs4912912|rs17209237|rs10050756| 
rs7719514|rs12653301 
DKK1 40 2 0.1249 rs11001581|rs7100461 
GRN 37 1 0.1319 rs114641762 
CHAT 189 5 0.1379 rs885834|rs11101179|rs1720367| 
rs4615945|rs74981858 
CHRNB2 39 5 0.1499 rs9616|rs9427094|rs12072348| 
rs67860750|rs4845653 
Syn3 1388 5 0.1718 rs2157188|rs9609643|rs2710348| 
rs180958069|rs5749521 
CCL2 43 1 0.1758 rs111843487 
IGF1 89 4 0.1888 rs1549593|rs10860862|rs12821878| 
rs80280982 
VEGFA 59 3 0.1908 rs9381248|rs3025006|rs699946 
NGF 135 2 0.1978 rs6537860|rs4320778 
MIF 77 1 0.2008 rs738807 
IL6 77 2 0.2338 rs2069840|rs62449498 
CASP3 94 2 0.2378 rs4647634|rs2696059 
MMP9 57 2 0.2537 rs73112805|rs3918253 
PRNP 94 2 0.2747 rs6052766|rs67017873 
SNCA 444 1 0.2927 rs187644542 
CDK5 53 2 0.3147 rs4148853|rs34403003 
IL1B 42 1 0.3147 rs3917381 
ADAM10 232 1 0.3197 rs544282 
NOS3 71 1 0.3197 rs12666075 
NRG1 2784 5 0.3227 rs147179882|rs2466068|rs7829383| 
rs2347071|rs11998153 
APBB1 119 1 0.3487 rs11040880 
LRRK2 360 3 0.3526 rs189800607|rs10878411|rs11564173 
OLIG2 123 2 0.3626 rs17632819|rs76708155 
NOS1 559 5 0.3826 rs67313272|rs4767542|rs816284| 
rs12228022|rs10850829 
HIF1A 82 1 0.4186 rs12891737 
FGF1 221 5 0.4326 rs1808258|rs2070715|rs249925| 
rs10041541|rs13179022 
TGFB1 131 1 0.5135 rs4803459 
IGF1R 520 5 0.5325 rs11631965|rs4966039|rs3743254| 
rs7166348|rs2272037 
FAS 175 1 0.5774 rs12767306 
APP 554 5 0.6214 rs2829960|rs6516705|rs13046930| 
rs6516715|rs117104544 
NTRK2 605 4 0.6264 rs17087710|rs28580203|rs1047896| 
rs1006446 
DYRK1A 380 1 0.6593 rs28550863 
ESR2 412 4 0.6983 rs1152576|rs4986938|rs10146107| 
rs12587140 
RELN 1552 5 0.7932 rs2299373|rs3819491|rs39377| 
rs1476446|rs694894 
ESR1 810 1 0.7972 rs55650062 
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ABCA2 61 0 1 NA 
ADRA2A 27 0 1 NA 
BDNF 122 0 1 NA 
CAV1 129 0 1 NA 
CDK5R1 24 0 1 NA 
CHRNA7 2 0 1 NA 
CNTF 29 0 1 NA 
FOS 48 0 1 NA 
GSK3B 329 0 1 NA 
HTR2A 203 0 1 NA 
NEUROD1 54 0 1 NA 
NPY 131 0 1 NA 
PLCG1 60 0 1 NA 
PSEN1 154 0 1 NA 
SIRT1 98 0 1 NA 
THRA 82 0 1 NA 
TNF 40 0 1 NA 
TNFR1A 4 0 1 NA 
TNFR1B 54 0 1 NA 
DLD 24 0 1 NA 
GLP1R 98 0 1 NA 
IFNG 19 0 1 NA 
Plau 30 0 1 NA 
PSEN2 19 0 1 NA 
SOD2 5 0 1 NA 
tp53 5 0 1 NA 
CST3 92 0 1 NA 
CHRM1 47 0 1 NA 
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Table 3. Association of rs9608282 in ADORA2A with neuroimaging phenotypes and memory 
composite scores with and without diagnosis (DX) adjustment. SNP-based association results 
(p-values) in the discovery sample for hippocampal volume, neurogenesis-related hippocampal 
sub-regions, memory performance, and CSF total tau level. 
 
 
rs9608282 p-value after adjusting for 
DX 
p-value without adjusting 
for DX 
Hippocampal Volume 3.29x10-4 1.14x10
-5
 
Neurogenesis-Related 
Hippocampal Sub-regions 
4.55x10
-3
 2.50x10
-4
 
Memory Composite Score 2.18x10
-1
 
7.45x10
-3
 
CSF Total Tau 2x10
-1
 2.3x10
-2
 
 
 
 
Table 4. Meta-analysis of ADORA2A with hippocampal volume in three independent cohorts: 
ADNI, AddNeuroMed and IMAS. 
 
 
ADNI 
p-value 
AddNeuroMed 
p-value 
IMAS 
p-value 
Meta-analysis 
p-value 
ADORA2A 5x10
-5
 2.1x10
-1
 2.95x10
-1
 
4.3x10
-5
 
 
 
Table 5. Meta-analysis of rs9608282 with hippocampal volume in three independent cohorts: 
ADNI, AddNeuroMed and IMAS.  
 
rs9608282 N Effect of rs9608282 (T) 
(β value) 
p-value 
ADNI 1563 146.9 1.14x10
-5
 
AddNeuroMed 218 362.4 2.34x10
-2
 
IMAS 59 -263.2 4.59x10
-2
 
Meta-analysis 1840  7.88x10-6 
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Figures: 
Figure 1. Genes playing roles in stem cells proliferation, differentiation, migration, and 
survival to new neurons during adult neurogenesis process. Glial-like radial stem cells 
(light blue); progenitors (pink); neuroblasts (purple); immature neurons (green); mature neurons 
(blue). 
Figure 2. Venn diagram of Adult neurogenesis-related genes and AD-susceptibility 
genes.  Manually curated neurogenesis and AD related gene. {(GoGene) U (Mango) U 
(Qiagen) U (GSEA)} ∩ {Pubmed Mining} = 401. AD-susceptibility genes (N=680) from AlzGene 
database and large-scale GWAS results. Eighty-one common genes were identified associated 
with both neurogenesis and AD. U: Union; ∩: Intersection. 
Figure 3. APOE ε4 and rs9608282 (ADORA2A) appear to exhibit independent, but 
opposite effect on hippocampal volume. Baseline hippocampal volume (adjusted for age, 
gender, ICV, MRI field strength) ± standard errors are shown based on (a) rs9608282 in 
ADORA2A (A2aR) across genotype groups. Presence of at least one copy of the minor allele 
(T) of rs9608282 was significantly associated with increased hippocampal volume (p = 0.002). 
Baseline hippocampal volume is also shown by (b) the number of APOE ε4 allele copies. 
Presence of at least one copy of the ε4 allele was significantly associated with decreased 
hippocampal volume (p < 0.0001). (c) For participants having APOE ε4 allele copies,  
participants carrying minor allele of rs9608282 had larger hippocampal volume than those who 
did not carry minor allele of the ADORA2A rs9608282 (p = 0.001). 
Figure 4. ADORA2A rs9608282 is associated with larger hippocampal volume in amyloid-
positive participants (classified by PET scan and/or CSF-amyloid beta level). For statistical 
analysis, each participant was classified by their amyloid status (positive versus negative) at the 
baseline visit (determined by standard cutoffs on [18F]Florbetapir PET scan and/or CSF amyloid 
level). The effect of the T allele on hippocampal volume was present in both amyloid-negative 
(left column) and amyloid-positive (right column) participants.  Upon statistical analysis, 
rs9608282 is significantly associated with hippocampal volume in amyloid-negative and even 
amyloid-positive participants (p = 0.027, p =0.015, respectively).  
Figure 5. ADORA2A rs9608282 is associated with larger hippocampal volume in 
Memantine non-users (NMDA (-)) and poorer memory performance in Memantine users 
(NMDA (+)). For statistical analysis, cognitively impaired participants were classified as either a 
Memantine user (NMDA (+)) or a Memantine non-user (NMDA (-)). (A) The rs9608282 T allele 
was associated with a larger mean hippocampal volume in Memantine non-user participants (p 
< 0.001). (B) Participants carrying at least one copy of minor allele (T) of the ADORA2A 
rs9608282 variant and using a NMDA-receptor antagonist had poorer memory performance. 
Figure 6. Association of memory composite score with rs9608282 in ADORA2A across 
genotype. Baseline memory composite score (adjusted for age, gender and education) ± 
standard errors are displayed based on rs9608282 genotype. Individuals with a TT genotype at 
the rs9608282 variant showed a 5% increase in memory performance relative to those with a 
GG genotype. 
Figure 7. Association of CSF tau level with rs9608282 in ADORA2A across genotype. CSF total 
tau level (adjusted for age and gender) ) ± standard errors are displayed based on rs9608282 
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genotype. Individuals with a TT genotype at the rs9608282 variant showed significant decrease 
in CSF tau level relative to those with a GG genotype. 
Figure 8. ADORA2A expression profiles across the hippocampus region. The square dot 
indicates the tissue sample location for human brain. In each square, heat map color represents 
the z-score over a probe ranging from green (z-score of -3 and below) through black to red (z-
score of +3 and above). Red squares represents overexpression of the ADORA2A in specific 
locations, most especially in CA1 and CA2.  
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Figure 7. 
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Figure 8.   
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Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated 
with hippocampal volume in mild cognitive impairment and Alzheimer’s disease 
 
Highlights: 
• Candidate pathways and genes which play a role in neurogenesis in the adult 
brain are manually-curated. 
• ADORA2A is significantly associated with hippocampal volume 
• A SNP (rs9608282) upstream of ADORA2A is associated with larger 
hippocampal volume and better memory performance. 
• rs9608282 may have a protective effect on brain structure and function in 
neurogenesis-related brain regions. 
• There is a significant interaction effect of NMDA-receptor antagonist use and the 
ADORA2A rs9608282-T on memory performance. 
 
 
